Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction

REFERENCES

• Tomlinson A, Bron AJ, Korb DR et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 2011; 52: 2006–2049.
   PubMed Web of Science ®Google Scholar
• Nichols KK, Foulks GN, Bron AJ et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52: 1922–1929.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Nichols JJ, Papas EB et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011; 52: 1994–2005.
   PubMed Web of Science ®Google Scholar
• Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013; 7: 1797–803.
   PubMedGoogle Scholar
• Geerling G, Tauber J, Baudouin C et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050–2064.
   PubMed Web of Science ®Google Scholar
• Lindsley K, Matsumura S, Hatef E et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev 2012; 5: CD005556.
   Google Scholar
• Asbell PA, Colby KA, Deng S et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008; 145: 951–958.
   PubMed Web of Science ®Google Scholar
• Asbell PA, Stapleton FJ, Wickstrom K et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci 2011; 52: 2065–2085.
   PubMed Web of Science ®Google Scholar
• Korb DR, Blackie CA. Debridement‐scaling: a new procedure that increases meibomian gland function and reduces dry eye symptoms. Cornea 2013; 32: 1554–1557.
   Web of Science ®Google Scholar
• Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea 2010; 29: 1145–1152.
   PubMed Web of Science ®Google Scholar
• Finis D, Hayajneh J, Konig C et al. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer‐masked trial. Ocul Surf 2014; 12: 146–154.
   PubMed Web of Science ®Google Scholar
• Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs 2015; 75: 1177–1185.
   PubMed Web of Science ®Google Scholar
• Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 2016; 35: 318–322.
   PubMed Web of Science ®Google Scholar
• Friedmann DP, Goldman MP. Dark circles: etiology and management options. Clin Plast Surg 2015; 42: 33–50.
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z. Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments. Br J Dermatol 2015; 173: 651–662.
   Web of Science ®Google Scholar
• Babilas P, Schreml S, Szeimies RM et al. Intense pulsed light (IPL): a review. Lasers Surg Med 2010; 42: 93–104.
   PubMed Web of Science ®Google Scholar
• Jiang X, Lv H, Song H et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol 2016; 2016: 1910694.
   Google Scholar
• Noecker R.J. Intense pulsed light therapy for treatment of rosacea and ocular surface disease. Presentation at American Society of Cataract and Refractive Surgery Annual Meeting; 2013 April 9–14; San Francisco, USA.
   Google Scholar
• Toyos R, Mcgill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3‐year retrospective study. Photomed Laser Surg 2015; 33: 41–46.
   PubMed Web of Science ®Google Scholar
• Craig JP, Chen Y‐H, Turnbull PRK. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2015; 56: 1965–1970.
   PubMed Web of Science ®Google Scholar
• Vora GK, Gupta PK. Intense pulsed light therapy for the treatment of evaporative dry eye disease. Curr Opin Ophthalmol 2015; 26: 314–318.
   PubMed Web of Science ®Google Scholar
• Lemp MA, Crews LA, Bron AJ et al. Distribution of aqueous‐deficient and evaporative dry eye in a clinic‐based patient cohort: a retrospective study. Cornea 2012; 31: 472–478.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick T. The validity and practicality of sun‐reactive skin types I through VI. Arch Dermatol 1988; 124: 869–871.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Murphy PJ. Measurement of ocular surface irritation on a linear interval scale with the ocular comfort index. Invest Ophthalmol Vis Sci 2007; 48: 4451–4458.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith J. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640–650.
   PubMed Web of Science ®Google Scholar
• Albietz J, Lenton L. Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease. Cornea 2006; 25: 1012–1019.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Tesavibul N, Mahawong W. A randomized double‐masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012; 31: 1386–1393.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Jacobsen G et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118: 615–621.
   PubMed Web of Science ®Google Scholar
• Miller KL, Walt JG, Mink DR et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthamol 2010; 128: 94–101.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Smith JA, Calonge M. Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 108–152.
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010; 51: 6125–6130.
   PubMed Web of Science ®Google Scholar
• Sambursky R, Tauber S, Friedberg M et al. Sensitivity and specificity of a point‐of‐care matrix metalloproteinase 9 immunoassay for diagnosing inflammation Related to Dry Eye. JAMA Ophthalmology 2013; 131: 24–28.
   PubMed Web of Science ®Google Scholar
• Golebiowski B, Papas E, Stapleton F. Assessing the sensory function of the ocular surface: implications of use of a non‐contact air jet aesthesiometer versus the Cochet‐Bonnet aesthesiometer. Exp Eye Res 2011; 92: 408–413.
   PubMed Web of Science ®Google Scholar
• Efron N, Morgan PB, Katsara SS. Validation of grading scales for contact lens complications. Ophthalmic Physiol Opt 2001; 21: 17–29.
   PubMed Web of Science ®Google Scholar
• Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification and grading. Ocular Surf 2003; 1: 107–126.
   PubMedGoogle Scholar
• Amparo F, Dastjerdi MH, Okanobo A et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013; 131: 715–723.
   PubMed Web of Science ®Google Scholar
• Amparo F, Jin Y, Hamrah P et al. What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease? Am J Ophthalmol 2014; 157: 69–77.e2.
   PubMed Web of Science ®Google Scholar
• Finis D, Pischel N, König C et al. Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine [in German] Ophthalmologe 2014; 111: 1050–1056.
   Web of Science ®Google Scholar
• Toyos R. Intense pulse light for dry‐eye disease measured by tear osmolarity. Presented at American Society of Cataract and Refractive Surgery Annual Meeting; April 9–14; San Francisco 2013.
   Google Scholar
• Lemp MA, Bron AJ, Baudouin C J et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151: 792–798.e1.
   PubMed Web of Science ®Google Scholar
• Potvin R, Makari S, Rapuano CJ. Tear film osmolarity and dry eye disease: a review of the literature. Clin Ophthalmol 2015; 9: 2039–2047.
   PubMed Web of Science ®Google Scholar
• Pei S, Inamadar AC, Adya KA et al. Light‐based therapies in acne treatment. Indian Dermatol Online J 2015; 6: 145–157.
   PubMedGoogle Scholar
• Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol 2008; 158: 442–455.
   PubMed Web of Science ®Google Scholar
• Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. Clin Ophthalmol 2011;5: 465–472.
   Google Scholar
• Lanza NL, Mcclellan A, Batawi H et al. Dry eye profiles in patients with a positive elevated surface matrix metalloproteinase 9 point‐of‐care test versus negative patients. Ocul Surf 2016; 14: 216–223.
   PubMed Web of Science ®Google Scholar
• Aragona P, Aguennouz MH, Rania L et al. Matrix Metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology 2015; 122: 62–71.
   PubMed Web of Science ®Google Scholar
• Enríquez‐de‐salamanca A, Castellanos E, Stern ME et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative‐type dry eye disease. Mol Vis 2010; 16: 862–873.
   PubMed Web of Science ®Google Scholar
• Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction. Adv Exp Med Biol 1994; 350: 293–298.
   PubMedGoogle Scholar
• O'dell L, Hom MM. Does in‐office manual expression for meibomian gland dysfuncion (MGD) work? Presented at American Academy of Optometry Annual Meeting New Orleans, October 2015; 150014.
   Google Scholar